BVI Medical completes a $1 billion strategic capital raise

News
Article

The capital raise was completed in partnership with global alternative asset management firm TPH.

Graphic of stock market and coins Image credit: AdobeStock/Kiattisak

Image credit: AdobeStock/Kiattisak

Global ophthalmic device company BVI Medical has announced the completion of its $1 billion strategic capital raise in partnership with global alternative asset management firm TPH. The investment fully refinanced BVI’s existing debt and added new equity from both TPG and new investors.1 The company plans to continue substantial growth in its portfolio of product offerings in light of the investment, according to a news release.

“This investment marks a pivotal moment for BVI as we scale our capabilities to meet the rising demand for advanced ophthalmic solutions,” said Shervin Korangy, president and CEO of BVI, in the release. “We are redefining the future of eye surgery and changing the competitive landscape by driving the launch of breakthrough technologies that will empower surgeons worldwide.”

Of recent note, BVI expanded its IOL manufacturing to Europe in order to meet global product demand, introduced new product lines including SERENITY and SERENITY Toric premium monofocal IOLs,2 and has engaged in a number of strategic acquisitions. Additionally, the company launched an education platform for ophthalmologists earlier this year, which allows physicians to connect across specialties to share insights and address complex cases.3

“TPG is proud to continue our partnership with BVI as it works to scale its global impact in ophthalmic care,” said Kendall Garrison, Partner at TPG. “The company has strengthened its market position while advancing patient care worldwide and this investment will further drive innovation and expansion. We look forward to supporting BVI’s continued success,” added John Schilling, MD, Co-Managing Partner at TPG Capital.

References:
  1. BVI Medical secures strategic capital raise to fuel global growth and innovation. News release. Businesswire. March 10, 2025. Accessed March 12, 2025. https://www.businesswire.com/news/home/20250306731225/en/BVI-Medical-Secures-Strategic-Capital-Raise-to-Fuel-Global-Growth-and-Innovation
  2. Joy J. BVI to launch new SERENITY and SERENITY Toric monofocal IOLs. Optometry Times. September 5, 2024. Accessed March 12, 2025. https://www.optometrytimes.com/view/bvi-to-launch-new-serenity-and-serenity-toric-monofocal-iols
  3. BVI Medical launches educational platform for ophthalmology professionals. News release. News release. BVI Medical. January 31, 2025. Accessed March 12, 2025. https://www.bvimedical.com/us/bvi-medical-launches-educational-platform-for-ophthalmology-professionals/

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
© 2025 MJH Life Sciences

All rights reserved.